Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Clinical Proof Equipment Supplied In Europe
12 equipment items found
Manufactured by:Caelus Health based inAmsterdam, NETHERLANDS
Intestinimonas: as basis of a drug to treat Type 2 Diabetes has been tested in animal trials; a first clinical Proof of Concept study will start in ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Manufactured by:Futura Medical based inGuildford, UNITED KINGDOM
Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements for both UK and US approval. Development currently on ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...
by:Blueback Physio based inPacé, FRANCE
As often in entrepreneurship, the idea of BlueBack was born from a personal story. The story of a young woman who at the age of twenty, was forbidden to practice sports because of back pain. After a long medical journey (specialized doctor, specialized rehabilitation center...), the real cause of the pathology is not treatable unless the resumption of a regular physical activity with as a ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
Manufactured by:Lattice Medical based inLoos, FRANCE
Lattice Medical is a biomedical start-up that was launched in October 2017; Patented 3D technology developed with CHU Lille-France that allows adipose tissue to naturally ...
Manufactured by:Ascelia Pharma AB based inMalmö, SWEDEN
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following ...